We have the same insight into the sources as we do OpenAI’s finances.
These type of stories are typically attributed to anonymous sources. So it’s impossible for a reader to conclude anything about the sources’ own credibility. So they usually rely on the credibility of the reporter or media org who’s published about it.
The Information is also reporting on this, but paywalled. IMO The Information does solid reporting.
https://www.theinformation.com/newsletters/applied-ai/openai...
Editing to add some of the Information’s reporting:
> Speaking at a panel at Davos moderated by The Information CEO Jessica Lessin, Friar suggested that in the field of drug discovery, her company could, for instance, take a “license to the drug that is discovered” using OpenAI’s technology. In other words, OpenAI would take a profit-sharing stake in the financial upside its AI creates for customers.
> Friar is no doubt familiar with older AI drug discovery firms such as Recursion that struck deals with pharmaceutical firms to give them big bounties for successful drugs identified by their tech. There aren’t many, if any, examples of such successes yet, though.
> OpenAI isn’t the only firm eyeing this opportunity. Its rivals Anthropic, Google DeepMind and Isomorphic Labs, an Alphabet subsidiary focusing on using AI for drug discovery, have also held discussions with early-stage biotechnology startups about data licensing or partnerships.